John A. Martignetti - Publications

Icahn School of Medicine at Mount Sinai, New York, NY, United States 
Cell Biology, Genetics, Molecular Biology

96 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Chen Y, Das S, Pandya D, Billaud J, Reva A, Roth A, Dottino PR, Hakonarson H, Martignetti J. Development and validation of targeted treatments for the rare tumor syndrome infantile myofibromatosis. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E22519  0.344
2019 Song X, Ji J, Gleason KJ, Yang F, Martignetti JA, Chen LS, Wang P. Insights into impact of DNA copy number alteration and methylation on the proteogenomic landscape in human ovarian cancer via a multi-omics integrative analysis. Molecular & Cellular Proteomics : McP. PMID 31227599 DOI: 10.1074/Mcp.Ra118.001220  0.374
2019 Pandya DS, Tomita S, Camacho O, Swierczek S, Camacho C, Engelman K, Polukort S, Padron MM, RoseFigura J, Irish J, Chuang L, Andikyan V, Cohen S, Fiedler P, Sieber S, ... ... Martignetti JA, et al. Abstract 2729: Development of a targeted liquid biopsy for early gynecologic cancer detection leads to discovery of a highly prevalent genomic landscape of cancer driver gene mutations in uterine tissue from women without cancer Cancer Research. 79: 2729-2729. DOI: 10.1158/1538-7445.Am2019-2729  0.426
2019 Pandya D, Camacho-Vanegas O, Camacho SC, Dottino P, Martignetti JA. Targeted Liquid Biopsy Detects Tumor-Specific TP53 Mutations in Early and Late Stage Ovarian Cancer [29O] Obstetrics & Gynecology. 133: 170-170. DOI: 10.1097/01.Aog.0000559484.56419.39  0.381
2019 Padron MMM, Camacho-Vanegas O, Pandya D, Camacho SC, Dottino P, Martignetti JA. Use of a Targeted Lynch Syndrome Next Generation Sequencing Panel in Women at Risk for or With Endometrial Cancer [32M] Obstetrics & Gynecology. 133: 149S-150S. DOI: 10.1097/01.Aog.0000559305.68974.C9  0.36
2018 Martignetti JA, Pandya D, Nagarsheth N, Chen Y, Camacho O, Tomita S, Brodman M, Ascher-Walsh C, Kolev V, Cohen S, Harkins T, Schadt E, Reva B, Sebra R, Dottino P. Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsy. Cold Spring Harbor Molecular Case Studies. PMID 30301868 DOI: 10.1101/mcs.a003269  0.309
2018 Schwartz M, Camacho-Vanegas O, Wood AM, Dashkoff M, Whitelock C, Harkins TT, Cohen CJ, Beddoe AM, Dottino P, Martignetti JA. Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a "Molecular Second Look". International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 29324546 DOI: 10.1097/Igc.0000000000001190  0.396
2018 Beaumont K, Copperman AB, Dottino P, Martignetti J, Schadt E, Sebra R. Multiparameter Single Cell Characterization of Ovarian Intratumor Heterogeneity [29A] Obstetrics & Gynecology. 131. DOI: 10.1097/01.Aog.0000532892.87767.De  0.324
2017 Wood A, Sandhu S, Dashkoff M, Camacho-Vanegas O, Kurihara L, Harkins T, Martignetti J, Makarov V, Dottino P. Abstract LB-276: Characterizing tumorigenesis of ovarian cancer across metastatic tumors and circulating, cell-free DNA Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-276  0.384
2017 Irish JC, Schumacher CA, Nair N, Camacho-Vanegas O, Figura JR, Wood A, Sandhu S, Chaluvadi S, Chupreta S, Kurihara L, Harkins T, Martignetti JA, Makarov V. Abstract 5392: Targeted next-generation sequencing of cell-free tumor DNA to longitudinally monitor cancer burden and progression Cancer Research. 77: 5392-5392. DOI: 10.1158/1538-7445.Am2017-5392  0.402
2017 Martignetti J, Nair N, Vanegas O, Rykunov D, Dashkoff M, Camacho S, Harkins T, Schumacher C, Irish J, Pereira E, Kendall S, Kalir T, Sebra R, Reva B, Dottino P. Mutation profiling of uterine lavage fluid detects early-stage endometrial cancers and discovers a prevalent landscape of driver mutations in women without cancer Gynecologic Oncology. 145: 126. DOI: 10.1016/J.Ygyno.2017.03.294  0.375
2016 Nair N, Camacho-Vanegas O, Rykunov D, Dashkoff M, Camacho SC, Schumacher CA, Irish JC, Harkins TT, Freeman E, Garcia I, Pereira E, Kendall S, Belfer R, Kalir T, Sebra R, ... ... Martignetti JA, et al. Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study. Plos Medicine. 13: e1002206. PMID 28027320 DOI: 10.1371/Journal.Pmed.1002206  0.379
2016 Martignetti JA, Chen Y, Camacho C, Silvers TR, Razak AR, Gabrail NY, Gerecitano JF, Kalir E, Pereira E, Evans BR, Ramus SJ, Huang F, Priedigkeit N, Rodriguez E, Donovan M, et al. INHIBITION OF THE NUCLEAR EXPORT RECEPTOR XPO1 AS A THERAPEUTIC TARGET FOR PLATINUM RESISTANT OVARIAN CANCER. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27649553 DOI: 10.1158/1078-0432.Ccr-16-1333  0.363
2016 Silvers TR, Dottino PR, Martignetti JA, Evans BR. Abstract B75: Increased basal autophagy decreases sensitivity to cisplatin in chemoresistant ovarian cancer. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B75  0.323
2016 Pereira E, Vanegas O, Anand S, Sebra R, Vanegas S, Garnar-Wortzel L, Nair N, Moshier E, Wooten M, Uzilov A, Chen R, Hayes M, Zakashansky K, Beddoe A, Schadt E, ... ... Martignetti J, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers Gynecologic Oncology. 141: 3-4. DOI: 10.1016/J.Ygyno.2016.04.036  0.34
2015 Pereira E, Camacho-Vanegas O, Anand S, Sebra R, Catalina Camacho S, Garnar-Wortzel L, Nair N, Moshier E, Wooten M, Uzilov A, Chen R, Prasad-Hayes M, Zakashansky K, Beddoe AM, Schadt E, ... ... Martignetti JA, et al. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers. Plos One. 10: e0145754. PMID 26717006 DOI: 10.1371/Journal.Pone.0145754  0.375
2015 Rubinsteyn A, Martignetti J, Pereira E, O'Donnell T, Ahuja A, Garnar-Wortzel L, Sebra R, Dottino P, Hammerbacher J, Schadt E. Heterogeneity of mutated tumor antigens in a single high grade ovarian serous carcinoma F1000research. 6. DOI: 10.7490/F1000Research.1098264.1  0.378
2015 Pereira EB, Camacho-Vanegas O, Anand S, Singh C, Uzilov A, Sebra R, Chappell D, Dottino P, Martignetti JA. Abstract 2398: Precision molecular biomarkers for the surveillance of gynecologic malignancies: Rapid and efficient pipeline for the design and highly sensitive detection of circulating tumor DNA Cancer Research. 75: 2398-2398. DOI: 10.1158/1538-7445.Am2015-2398  0.414
2015 Evans BR, Silvers TR, Chen YA, Garcia J, Camacho C, Sharp AJ, Garag P, Koduru SV, Billaud J, Halpert RL, Dottino PR, Landesman Y, Shacham S, Martignetti JA. Abstract 1758: Deconstructing protein and gene expression pathways to define the anticancer effects of XPO1 inhibition in ovarian cancer Cancer Research. 75: 1758-1758. DOI: 10.1158/1538-7445.Am2015-1758  0.397
2014 Martignetti J, Razak AR, Chen Y, Gabrail NY, Gericitano JF, Camacho C, Pereira E, Evans B, Dottino P, McCauley D, Shacham S, Rashal T, Saint-Martin J, Shacham E, Vincent D, et al. 888PPRECLINICAL AND EARLY CLINICAL ACTIVITY OF THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) EXPORTIN 1 (XPO1) ANTAGONIST SELINEXOR (KPT-330) IN PATIENTS (PTS) WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER (OVCA). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv310. PMID 28170968 DOI: 10.1093/Annonc/Mdu338.14  0.314
2014 Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, Halpert R, Billaud JN, Dottino P, Martignetti JA. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma. Gynecologic Oncology. 134: 591-8. PMID 24995581 DOI: 10.1016/J.Ygyno.2014.06.025  0.769
2014 Wang Z, Wu B, Mosig RA, Chen Y, Ye F, Zhang Y, Gong W, Gong L, Huang F, Wang X, Nie B, Zheng H, Cui M, Wang Y, Wang J, ... ... Martignetti JA, et al. STK11 domain XI mutations: candidate genetic drivers leading to the development of dysplastic polyps in Peutz-Jeghers syndrome. Human Mutation. 35: 851-8. PMID 24652667 DOI: 10.1002/Humu.22549  0.768
2014 Martignetti JA, Camacho-Vanegas O, Priedigkeit N, Camacho C, Pereira E, Lin L, Garnar-Wortzel L, Miller D, Losic B, Shah H, Liao J, Ma J, Lahiri P, Chee M, Schadt E, et al. Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA. Neoplasia (New York, N.Y.). 16: 97-103. PMID 24563622 DOI: 10.1593/Neo.131900  0.391
2014 Martignetti J, Razak ARA, Chen Y, Gabrail NY, Gerecitano JF, Camacho C, Pereira E, Dottino PR, Shacham S, McCauley D, Rashal T, Saint-Martin J, Shacham E, Vincett D, Kauffman M, et al. Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa). Journal of Clinical Oncology. 32: 5522-5522. DOI: 10.1200/Jco.2014.32.15_Suppl.5522  0.379
2014 Martignetti JA, Cohen S, Mosig R, Halpert R, Billaud J, Dottino P. Abstract 5593: Transcriptome and pathway analysis identifies IRF1 as a predictor of progression free and overall survival in ovarian carcinoma Cancer Research. 74: 5593-5593. DOI: 10.1158/1538-7445.Am2014-5593  0.778
2014 Martignetti JA, Camacho-Vanegas O, Priedigkeit N, Camacho-Vanegas C, Pereira E, Lin L, Losic B, Shah h, Liao J, Ma J, Lahiri P, Chee M, Schadt E, Dottino P. Abstract 4712: Personalized ovarian cancer surveillance and detection of a therapeutic drug target in circulating tumor DNA Cancer Research. 74: 4712-4712. DOI: 10.1158/1538-7445.Am2014-4712  0.394
2014 Billaud J, Cohen S, Mosig R, Halpert R, Dottino P, Martignetti J. 869: Transcriptome and pathway analysis identifies IRF1 as a predictor of progression free and overall survival in ovarian carcinoma European Journal of Cancer. 50. DOI: 10.1016/S0959-8049(14)50772-1  0.747
2014 Pereira EB, Evans B, Vanegas OC, Dottino P, Martignetti J. Establishment and combined genomic and proteomic characterization of patient-derived ovarian cancer cell lines Gynecologic Oncology. 133: 125. DOI: 10.1016/J.Ygyno.2014.03.327  0.333
2013 Castberg FC, Kjaergaard S, Mosig RA, Lobl M, Martignetti C, Martignetti JA, Myrup C, Zak M. Multicentric osteolysis with nodulosis and arthropathy (MONA) with cardiac malformation, mimicking polyarticular juvenile idiopathic arthritis: case report and literature review. European Journal of Pediatrics. 172: 1657-63. PMID 23900523 DOI: 10.1007/S00431-013-2102-8  0.741
2013 Martignetti JA, Tian L, Li D, Ramirez MC, Camacho-Vanegas O, Camacho SC, Guo Y, Zand DJ, Bernstein AM, Masur SK, Kim CE, Otieno FG, Hou C, Abdel-Magid N, Tweddale B, et al. Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis. American Journal of Human Genetics. 92: 1001-7. PMID 23731542 DOI: 10.1016/J.Ajhg.2013.04.024  0.363
2013 Camacho-Vanegas O, Till J, Miranda-Lorenzo I, Ozturk B, Camacho SC, Martignetti JA. Shaking the family tree: identification of novel and biologically active alternatively spliced isoforms across the KLF family of transcription factors. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 27: 432-6. PMID 23134681 DOI: 10.1096/Fj.12-220319  0.346
2013 Mosig RA, Martignetti JA. Loss of MMP-2 in murine osteoblasts upregulates osteopontin and bone sialoprotein expression in a circuit regulating bone homeostasis. Disease Models & Mechanisms. 6: 397-403. PMID 22917927 DOI: 10.1242/Dmm.007914  0.759
2013 Favier R, DiFeo A, Hezard N, Fabre M, Bedossa P, Martignetti JA. A new feature of the MYH9-related syndrome: chronic transaminase elevation. Hepatology (Baltimore, Md.). 57: 1288-9. PMID 22806255 DOI: 10.1002/Hep.25913  0.523
2013 Chen Y, Kalir E, Camacho-Vanegas C, Huang F, Pereira E, Landesman Y, McCauley D, Mirza MR, Kauffman M, Shacham S, Dottino PR, Martignetti JA. Abstract 2163: Increased overall survival in platinum-resistant ovarian cancer: paradigmatic use of novel SINE (selective inhibitor of nuclear export), which restores p53 nuclear localization and activation. Cancer Research. 73: 2163-2163. DOI: 10.1158/1538-7445.Am2013-2163  0.391
2012 Evans BR, Mosig RA, Lobl M, Martignetti CR, Camacho C, Grum-Tokars V, Glucksman MJ, Martignetti JA. Mutation of membrane type-1 metalloproteinase, MT1-MMP, causes the multicentric osteolysis and arthritis disease Winchester syndrome. American Journal of Human Genetics. 91: 572-6. PMID 22922033 DOI: 10.1016/J.Ajhg.2012.07.022  0.756
2012 Camacho-Vanegas O, Camacho SC, Till J, Miranda-Lorenzo I, Terzo E, Ramirez MC, Schramm V, Cordovano G, Watts G, Mehta S, Kimonis V, Hoch B, Philibert KD, Raabe CA, Bishop DF, ... ... Martignetti JA, et al. Primate genome gain and loss: a bone dysplasia, muscular dystrophy, and bone cancer syndrome resulting from mutated retroviral-derived MTAP transcripts. American Journal of Human Genetics. 90: 614-27. PMID 22464254 DOI: 10.1016/J.Ajhg.2012.02.024  0.42
2012 Calderon MR, Verway M, An BS, DiFeo A, Bismar TA, Ann DK, Martignetti JA, Shalom-Barak T, White JH. Ligand-dependent corepressor (LCoR) recruitment by Kruppel-like factor 6 (KLF6) regulates expression of the cyclin-dependent kinase inhibitor CDKN1A gene. The Journal of Biological Chemistry. 287: 8662-74. PMID 22277651 DOI: 10.1074/Jbc.M111.311605  0.636
2012 Mosig RA, Lin L, Senturk E, Shah H, Huang F, Schlosshauer P, Cohen S, Fruscio R, Marchini S, D'Incalci M, Sachidanandam R, Dottino P, Martignetti JA. Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer. Journal of Ovarian Research. 5: 4. PMID 22272937 DOI: 10.1186/1757-2215-5-4  0.779
2012 Mosig RA, Lobl M, Senturk E, Shah H, Cohen S, Chudin E, Fruscio R, Marchini S, D'Incalci M, Sachidanandam R, Dottino P, Martignetti JA. IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer. Journal of Ovarian Research. 5: 3. PMID 22264331 DOI: 10.1186/1757-2215-5-3  0.778
2012 Camacho-Vanegas O, Camacho SC, Till J, Miranda-Lorenzo I, Terzo E, Ramirez MC, Schramm V, Cordovano G, Watts G, Mehta S, Kimonis V, Hoch B, Philibert KD, Raabe CA, Bishop DF, ... ... Martignetti JA, et al. Abstract LB-89: Discovery and characterization of novel MTAP splice variants resulting in a hereditary form of osteosarcoma and demonstration of their dysregulation in sporadic forms of this cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-89  0.464
2012 Chen Y, Kalir E, Priedigkeit N, Kalir T, Liu Y, Hu W, Sood A, Radu A, Dottino P, Martignetti J. Follicle-stimulating hormone receptor expression analysis in serous ovarian tumors suggests a disease continuum from low malignant potential to low-grade carcinoma Gynecologic Oncology. 125. DOI: 10.1016/J.Ygyno.2011.12.348  0.331
2012 Mosig R, Lobl M, Cohen S, Chudin E, Fruscio R, Marchini S, D'Incalci M, Sachidanandam R, Dottino P, Martignetti J. Insulin-like growth factor binding protein-4 (IGFBP-4) tumor and serum levels are increased across all stages of epithelial ovarian cancer Gynecologic Oncology. 125. DOI: 10.1016/J.Ygyno.2011.12.225  0.763
2011 Sanborn KB, Mace EM, Rak GD, Difeo A, Martignetti JA, Pecci A, Bussel JB, Favier R, Orange JS. Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity. Blood. 118: 5862-71. PMID 22123909 DOI: 10.1182/Blood-2011-03-344846  0.578
2011 Agnani D, Camacho-Vanegas O, Camacho C, Lele S, Odunsi K, Cohen S, Dottino P, Martignetti JA. Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression. Journal of Ovarian Research. 4: 18. PMID 22017790 DOI: 10.1186/1757-2215-4-18  0.388
2011 Deuquet J, Lausch E, Guex N, Abrami L, Salvi S, Lakkaraju A, Ramirez MC, Martignetti JA, Rokicki D, Bonafe L, Superti-Furga A, van der Goot FG. Hyaline fibromatosis syndrome inducing mutations in the ectodomain of anthrax toxin receptor 2 can be rescued by proteasome inhibitors. Embo Molecular Medicine. 3: 208-21. PMID 21328543 DOI: 10.1002/Emmm.201100124  0.358
2011 Poopak B, Rezvani H, Difeo A, Martignetti JA, Khosravipour G, Yousefian A, Farahani K, Haghnejad Doshanlo F, Saki N. The first report of homozygous May-Hegglin anomaly E1841K mutation. European Journal of Haematology. 86: 357. PMID 21083612 DOI: 10.1111/J.1600-0609.2010.01553.X  0.61
2011 Radbill BD, Gupta R, Ramirez MC, DiFeo A, Martignetti JA, Alvarez CE, Friedman SL, Narla G, Vrabie R, Bowles R, Saiman Y, Bansal MB. Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression. Digestive Diseases and Sciences. 56: 406-16. PMID 20563750 DOI: 10.1007/S10620-010-1296-0  0.588
2011 Mosig R, Senturk E, Shah H, Cohen S, Sachidanandam R, Eliasen C, Glucksman M, Chee M, Dottino P, Martignetti J. RNASeq identifies germline and tumor-specific mutations in a hereditary cervical cancer syndrome: Successful proof-of-principle study for gynecologic cancer gene discovery Gynecologic Oncology. 120: S60. DOI: 10.1016/J.Ygyno.2010.12.145  0.793
2011 Bradley W, Dottino P, Rahaman J, DiFeo A, Martignetti J. The tumor suppressor KLF6, lost in a majority of ovarian cancer cases, represses VEGF expression levels Gynecologic Oncology. 120: S57. DOI: 10.1016/J.Ygyno.2010.12.137  0.66
2011 DiFeo A, Sennet R, Huang F, Levine D, Kalir T, van de Rijn M, Dottino P, Martignetti J. KLF6-SV1 is a novel uterine leiomyosarcoma gene: From transgenic mouse model to human disease Gynecologic Oncology. 120: S8. DOI: 10.1016/J.Ygyno.2010.12.022  0.591
2010 Rodríguez E, Aburjania N, Priedigkeit NM, DiFeo A, Martignetti JA. Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function. Plos One. 5. PMID 20844588 DOI: 10.1371/Journal.Pone.0012639  0.647
2010 Senturk E, Cohen S, Dottino PR, Martignetti JA. A critical re-appraisal of BRCA1 methylation studies in ovarian cancer. Gynecologic Oncology. 119: 376-83. PMID 20797776 DOI: 10.1016/J.Ygyno.2010.07.026  0.425
2009 DiFeo A, Narla G, Martignetti JA. Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment. The Mount Sinai Journal of Medicine, New York. 76: 557-66. PMID 20014424 DOI: 10.1002/Msj.20150  0.684
2009 Rodríguez E, Martignetti JA. The Krüppel traffic report: cooperative signals direct KLF8 nuclear transport. Cell Research. 19: 1041-3. PMID 19727130 DOI: 10.1038/Cr.2009.103  0.321
2009 Sanborn KB, Rak GD, Maru SY, Demers K, Difeo A, Martignetti JA, Betts MR, Favier R, Banerjee PP, Orange JS. Myosin IIA associates with NK cell lytic granules to enable their interaction with F-actin and function at the immunological synapse. Journal of Immunology (Baltimore, Md. : 1950). 182: 6969-84. PMID 19454694 DOI: 10.4049/Jimmunol.0804337  0.578
2009 Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, Martignetti JA. KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Research. 69: 4733-41. PMID 19435908 DOI: 10.1158/0008-5472.Can-08-4282  0.663
2009 Deuquet J, Abrami L, Difeo A, Ramirez MC, Martignetti JA, van der Goot FG. Systemic hyalinosis mutations in the CMG2 ectodomain leading to loss of function through retention in the endoplasmic reticulum. Human Mutation. 30: 583-9. PMID 19191226 DOI: 10.1002/Humu.20872  0.622
2009 Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, McClinch K, Hatami R, Scheer E, Kremer-Tal S, Martignetti JA, Hui A, Leung WK, Friedman SL, Narla G. Functional role of the KLF6 tumour suppressor gene in gastric cancer. European Journal of Cancer (Oxford, England : 1990). 45: 666-76. PMID 19101139 DOI: 10.1016/J.Ejca.2008.11.009  0.661
2009 DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 12: 1-7. PMID 19097929 DOI: 10.1016/J.Drup.2008.11.001  0.698
2009 Tuysuz B, Mosig R, Altun G, Sancak S, Glucksman MJ, Martignetti JA. A novel matrix metalloproteinase 2 (MMP2) terminal hemopexin domain mutation in a family with multicentric osteolysis with nodulosis and arthritis with cardiac defects. European Journal of Human Genetics : Ejhg. 17: 565-72. PMID 18985071 DOI: 10.1038/Ejhg.2008.204  0.763
2008 Hartel M, Narla G, Wente MN, Giese NA, Martignoni ME, Martignetti JA, Friess H, Friedman SL. Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. European Journal of Cancer (Oxford, England : 1990). 44: 1895-903. PMID 18691883 DOI: 10.1016/J.Ejca.2008.06.030  0.416
2008 Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. The Journal of Clinical Investigation. 118: 2711-21. PMID 18596922 DOI: 10.1172/Jci34780  0.669
2008 Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, Llovet JM, Friedman SL. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology. 134: 1521-31. PMID 18471523 DOI: 10.1053/J.Gastro.2008.02.015  0.384
2008 DiFeo A, Feld L, Rodriguez E, Wang C, Beer DG, Martignetti JA, Narla G. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Research. 68: 965-70. PMID 18250346 DOI: 10.1158/0008-5472.Can-07-2604  0.65
2008 Lindvall LE, Kormeili T, Chen E, Ramirez MC, Grum-Tokars V, Glucksman MJ, Martignetti JA, Zaragoza MV, Dyson SW. Infantile systemic hyalinosis: Case report and review of the literature. Journal of the American Academy of Dermatology. 58: 303-7. PMID 18222328 DOI: 10.1016/J.Jaad.2007.06.008  0.306
2007 Teixeira MS, Camacho-Vanegas O, Fernandez Y, Narla G, DiFeo A, Lee B, Kalir T, Friedman SL, Schlecht NF, Genden EM, Urken M, Brandwein-Gensler M, Martignetti JA. KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. International Journal of Cancer. 121: 1976-83. PMID 17621627 DOI: 10.1002/Ijc.22926  0.689
2007 Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, Chan AM, Friedman SL, Feuerstein BG, Martignetti JA. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. International Journal of Cancer. Journal International Du Cancer. 121: 1390-5. PMID 17514651 DOI: 10.1002/Ijc.22809  0.678
2007 Mosig RA, Dowling O, DiFeo A, Ramirez MC, Parker IC, Abe E, Diouri J, Aqeel AA, Wylie JD, Oblander SA, Madri J, Bianco P, Apte SS, Zaidi M, Doty SB, ... ... Martignetti JA, et al. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Human Molecular Genetics. 16: 1113-23. PMID 17400654 DOI: 10.1093/Hmg/Ddm060  0.765
2007 Phadke SR, Ramirez M, Difeo A, Martignetti JA, Girisha KM. Torg-Winchester syndrome: lack of efficacy of pamidronate therapy. Clinical Dysmorphology. 16: 95-100. PMID 17351352 DOI: 10.1097/Mcd.0B013E3280147187  0.602
2007 Antaya RJ, Cajaiba MM, Madri J, Lopez MA, Ramirez MCM, Martignetti JA, Reyes-Múgica M. Juvenile hyaline fibromatosis and infantile systemic hyalinosis overlap associated with a novel mutation in capillary morphogenesis protein-2 gene American Journal of Dermatopathology. 29: 99-103. PMID 17284973 DOI: 10.1097/01.Dad.0000245636.39098.E5  0.333
2007 Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM, Banck M, Zimran E, Thorgeirsson SS, Mazzaferro V, Bruix J, ... Martignetti JA, et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. Journal of Hepatology. 46: 645-54. PMID 17196295 DOI: 10.1016/J.Jhep.2006.10.012  0.625
2007 Kupferman ME, Rhee JS, Teixeira MS, Camacho-Vanegas O, Fernandez Y, Narla G, Difeo A, Schlecht NF, Brandwein-Gensler M, Martignetti JA. 10:30: KLF6 LOH Is Linked to Recurrence and Lower Survival in HNSSC Otolaryngology–Head and Neck Surgery. 137: P77-P78. DOI: 10.1016/J.Otohns.2007.06.095  0.583
2006 Utsch B, DiFeo A, Kujat A, Karle S, Schuster V, Lenk H, Jacobs U, Müller M, Dötsch J, Rascher W, Reutter H, Martignetti JA, Ludwig M, Tröbs RB. Bladder exstrophy and Epstein type congenital macrothrombocytopenia: evidence for a common cause? American Journal of Medical Genetics. Part A. 140: 2251-3. PMID 16969870 DOI: 10.1002/Ajmg.A.31454  0.581
2006 DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Martignetti JA. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3730-9. PMID 16778100 DOI: 10.1158/1078-0432.Ccr-06-0054  0.676
2006 DiFeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE, Friedman SL, Walsh MJ, Martignetti JA. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene. 25: 6026-31. PMID 16702959 DOI: 10.1038/Sj.Onc.1209611  0.64
2006 Kirschenbaum A, Liu XH, Yao S, Narla G, Friedman SL, Martignetti JA, Levine AC. Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones. Carcinogenesis. 27: 216-24. PMID 16123118 DOI: 10.1093/Carcin/Bgi219  0.316
2005 Park JH, Eliyahu E, Narla G, DiFeo A, Martignetti JA, Schuchman EH. KLF6 is one transcription factor involved in regulating acid ceramidase gene expression Biochimica Et Biophysica Acta - Gene Structure and Expression. 1732: 82-87. PMID 16500425 DOI: 10.1016/J.Bbaexp.2006.01.002  0.637
2005 Li D, Yea S, Dolios G, Martignetti JA, Narla G, Wang R, Walsh MJ, Friedman SL. Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation. Cancer Research. 65: 9216-25. PMID 16230382 DOI: 10.1158/0008-5472.Can-05-1040  0.395
2005 Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, Chan AM, Friedman SL, Martignetti JA. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Research. 65: 5761-8. PMID 15994951 DOI: 10.1158/0008-5472.Can-05-0217  0.671
2005 Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen SJ, Isaacs SD, Walsh PC, ... ... Martignetti JA, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Research. 65: 1213-22. PMID 15735005 DOI: 10.1158/0008-5472.Can-04-4249  0.658
2004 Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, Katz A, Bruix J, Bioulac-Sage P, Martignetti JA, Friedman SL. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (Baltimore, Md.). 40: 1047-52. PMID 15486921 DOI: 10.1002/Hep.20460  0.656
2004 Kimmelman AC, Qiao RF, Narla G, Banno A, Lau N, Bos PD, Nuñez Rodriguez N, Liang BC, Guha A, Martignetti JA, Friedman SL, Chan AM. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene. 23: 5077-83. PMID 15064720 DOI: 10.1038/Sj.Onc.1207662  0.437
2004 Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, Hod E, Harpaz N, Goldberg S, Tal-Kremer S, Eng FJ, Arthur MJ, Martignetti JA, Friedman SL. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology. 126: 1090-103. PMID 15057748 DOI: 10.1053/J.Gastro.2004.01.005  0.436
2003 Toren A, Rozenfeld-Granot G, Heath KE, Amariglio N, Rocca B, Crosson J, Epstein CJ, Laghi F, Landolfi R, Carlsson LE, Argraves S, Bizzaro N, Moxey-Mims M, Brok-Simoni F, Martignetti JA, et al. MYH9 spectrum of autosomal-dominant giant platelet syndromes: unexpected association with fibulin-1 variant-D inactivation. American Journal of Hematology. 74: 254-62. PMID 14635206 DOI: 10.1002/Ajh.10425  0.361
2003 Dowling O, Difeo A, Ramirez MC, Tukel T, Narla G, Bonafe L, Kayserili H, Yuksel-Apak M, Paller AS, Norton K, Teebi AS, Grum-Tokars V, Martin GS, Davis GE, Glucksman MJ, ... Martignetti JA, et al. Mutations in capillary morphogenesis gene-2 result in the allelic disorders juvenile hyaline fibromatosis and infantile systemic hyalinosis. American Journal of Human Genetics. 73: 957-66. PMID 12973667 DOI: 10.1086/378781  0.658
2003 Narla G, Friedman SL, Martignetti JA. Krüppel cripples prostate cancer: KLF6 progress and prospects. The American Journal of Pathology. 162: 1047-52. PMID 12651597 DOI: 10.1016/S0002-9440(10)63901-6  0.344
2003 Hirshfeld J, Narla G, Difeo A, Kalir T, Buller R, Friedman S, Martignetti J. KLF6 POLYMORPHISM IN PROSTATE CANCER REVEALS A NOVEL MECHANISM OF TUMOR SUPPRESSOR GENE INACTIVATION. Journal of Investigative Medicine. 51: 336.2-337. DOI: 10.1136/Jim-51-06-21  0.647
2001 Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA, Friedman SL. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science (New York, N.Y.). 294: 2563-6. PMID 11752579 DOI: 10.1126/Science.1066326  0.434
2001 Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, Savige J, Denison JC, Gregory MC, White JG, Barker DF, Greinacher A, Epstein CJ, Glucksman MJ, Martignetti JA. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. American Journal of Human Genetics. 69: 1033-45. PMID 11590545 DOI: 10.1086/324267  0.35
2001 Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, Mayouf SA, Sheth KV, Eid WA, Dowling O, Harris J, Glucksman MJ, Bahabri S, Meyer BF, Desnick RJ. Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nature Genetics. 28: 261-5. PMID 11431697 DOI: 10.1038/90100  0.387
2000 Yang T, Martignetti JA, Massa SM, Longo FM. Leukocyte common-antigen-related tyrosine phosphatase receptor: altered expression of mRNA and protein in the New England Deaconess Hospital rat line exhibiting spontaneous pheochromocytoma. Carcinogenesis. 21: 125-31. PMID 10657947 DOI: 10.1093/Carcin/21.2.125  0.352
2000 Martignetti JA, Gelb BD, Pierce H, Picci P, Desnick RJ. Malignant fibrous histiocytoma: inherited and sporadic forms have loss of heterozygosity at chromosome bands 9p21-22-evidence for a common genetic defect. Genes, Chromosomes and Cancer. 27: 191-195. PMID 10612808 DOI: 10.1002/(Sici)1098-2264(200002)27:2<191::Aid-Gcc11>3.0.Co;2-L  0.37
1999 Wasserstein MP, Martignetti JA, Zeitlin R, Lumerman H, Solomon M, Grace ME, Desnick RJ. Type 1 Gaucher disease presenting with extensive mandibular lytic lesions: identification and expression of a novel acid beta-glucosidase mutation. American Journal of Medical Genetics. 84: 334-9. PMID 10340647 DOI: 10.1002/(Sici)1096-8628(19990604)84:4<334::Aid-Ajmg5>3.0.Co;2-P  0.312
1999 Martignetti JA, Desnick RJ, Aliprandis E, Norton KI, Hardcastle P, Nade S, Gelb BD. Diaphyseal medullary stenosis with malignant fibrous histiocytoma: a hereditary bone dysplasia/cancer syndrome maps to 9p21-22. American Journal of Human Genetics. 64: 801-7. PMID 10053015 DOI: 10.1086/302297  0.39
1998 Martignetti JA, Desnick RJ, Gelb BD. From Hereditary Cancer Syndrome to Sporadic Cancer Etiology: Genetic Linkage of DMS-MFH to Chromosome 9p21-22 • 724 Pediatric Research. 43: 126-126. DOI: 10.1203/00006450-199804001-00745  0.404
1996 Norton KI, Wagreich JM, Granowetter L, Martignetti JA. Diaphyseal medullary stenosis (sclerosis) with bone malignancy (malignant fibrous histiocytoma): Hardcastle syndrome. Pediatric Radiology. 26: 675-7. PMID 8781110 DOI: 10.1007/Bf01356833  0.309
Show low-probability matches.